In October 2020, SARS-CoV-2 lineage B.1.617 emerged in India, causing an exponential increase in COVID-19 cases across the country. The lineage is further divided into three subgroups: B.1.617.1, B.1.617.2, and B.1.617.3, of which the B.1.617.2 variant (also known as Delta variant) has been designated as Variant of Concern (VOC) by WHO because of significantly increased infectivity. The mutations L452R and E484Q, along with P681R in the furin cleavage site are reported to lead to increased ACE2 binding and rate of S1-S2 cleavage resulting in better transmissibility, and capacity to escape the binding and neutralization by some monoclonal antibodies. The combined detection of these three mutations will contribute to identifying B.1.617.2.
This product is intended to detect L452R, E484Q, and P681R mutations in S gene of SARS-CoV-2 and help to identify B.1.617.2 for research purpose.
Our R&D team is closely tracking the reported SARS-CoV-2 variants worldwide and design assays for detecting emerging mutations related to increased infectiousness, immune escape, vaccine efficacy, and therapeutic medicines. Assays for these emerging mutation targets of interest will be available upon request.
> Whether the specimen is Delta B.1.617.2. If not,
> Whether the specimen is B.1.617. If not,
> Whether the specimen is SARS-CoV-2 positive.
* Semi-automated interpretation tool available for other real-time PCR instruments
Target |
ORF1a/b, L452R, E484Q, and P681R |
Coincidence with internal positive reference |
100% |
Coincidence with internal negative reference |
100% |
Limit of detection |
500 copies/mL |
Sample input volume |
5μL |
Sample type |
Nasopharyngeal swabs, throat swabs, sputum specimens. |
CE
I am interested in more information on the following Bioperfectus product
Fieids marked with an asterisk(*) are required